Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
SALT LAKE CITY, May 30, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference at 10:00 a.m. PDT on June 13, 2017, at the Terranea Resort in Rancho Palos Verdes, California.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
